Promotes Dr. Shane
Morris to SVP Product Development and Regulatory
Affairs
TSX/NYSE: ACB
EDMONTON, Nov. 14, 2018 /CNW/ - Aurora Cannabis Inc. (TSX:
ACB) (NYSE: ACB) (Frankfurt: 21P;
WKN: A1C4WM) is pleased to announce the appointment of Dr.
Jonathan Page, PhD as the Company's
Chief Science Officer.
In this new role, Dr. Page will oversee all science-related
projects at the Company. The Aurora science team develops
innovative products for the medical, wellness and adult consumer
markets and focuses on delivering industry-leading cultivation
results in terms of yields, consistency, quality and efficiency.
Dr. Page is a globally renowned cannabis scientist, with 37
peer-reviewed publications, who was the co-lead of the Canadian
team of scientists who first sequenced the cannabis genome. His
work also helped discover the biochemical pathways leading to the
major cannabinoids. Prior to his appointment, Dr. Page served as
CEO of recently acquired Anandia Labs, the world-leading
cannabis-focused science company he co-founded.
"We are thrilled to have Jonathan join the Aurora team as Chief
Science Officer," said CEO Terry
Booth. "Jonathan's knowledge of the cannabis plant and its
applications make him a globally recognized leader in the cannabis
sector. With this appointment we are well-positioned to continue to
innovate through the research our teams are involved in and drive
new commercial products."
Aurora has ingrained scientific methods throughout the Company,
which it uses to drive efficiencies, medical and plant discovery
and product innovation. That approach will only increase with Dr.
Page's appointment. With more than 40 PhD- and MSc-level
researchers, Aurora has cutting-edge research programs designed to
develop competitive advantages.
"Science is a critical to global competitiveness and Aurora is
the cannabis industry leader on this front," said Dr. Page.
"Science is in Aurora's DNA. I'm very excited to take on this new
position and work with our science teams to take the development of
the cannabis plant and its applications to the next level."
An entrepreneurial scientist, Dr. Page co-founded Anandia Labs,
which specializes in cannabis genetics, metabolite profiling, plant
breeding, disease characterization, and cultivar certification, as
well as providing third party independent testing services to
producers and patient-cultivators. Dr. Page is an adjunct professor
in the Botany Department at the University of
British Columbia (UBC) who received his PhD from UBC,
undertook postdoctoral training in Germany, and for a decade directed a lab at
the National Research Council. Dr. Page
is also an accomplished inventor with eight issued patents or
patent applications, and a frequent lecturer on cannabis science at
international conferences.
Anandia will continue to operate independently of Aurora. Dr.
John Coleman, PhD will be taking
over as President at Anandia.
Dr. Shane Morris promoted to
SVP Product Development and Regulatory Affairs
Aurora is also pleased to announce the promotion of Dr.
Shane Morris, PhD to the role of
Senior Vice-President of product development and regulatory
affairs. Dr. Morris had been the Vice-President in this role
previously.
"Innovation and consumer focused products will be critical for
future success in the global cannabis sector," said Dr.
Shane Morris. "Discovery, technical
skills, quality excellence and regulatory expertise all need to be
integrated in order to develop and successfully introduce those
products that the global markets are looking for. Building a
collaborative global team that can execute across these areas and
turn ideas into revenue is what sets Aurora apart as a world leader
in the cannabis industry."
Dr. Morris and his team are responsible for numerous product
innovations at Aurora, including the recent launch of Aurora Cloud, the industry's only vape-ready CBD
oil cartridge available on the Canadian medical cannabis
market.
"Shane's promotion is based on his incredible track record that
has positioned Aurora's leading product development team at the
cutting edge of our industry," said CEO Terry Booth. "Shane has delivered and proven
time and again that he is exceptionally well suited to lead this
function."
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 20 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland, have achieved this level of
certification.
In addition to Aurora's rapid organic growth and strong
execution on strategic M&A, which to date includes 15 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
and the pending acquisition of ICC – Aurora is distinguished by its
reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc.
(private), Evio Beauty Group (private), Wagner Dimas (private), CTT
Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX nor its Regulation Services Provider (as that
term is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Terry Booth, CEO
Aurora Cannabis Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-appoints-dr-jonathan-page-as-chief-science-officer-300750502.html
SOURCE Aurora Cannabis Inc.